DOCSLIB.ORG

The Big Pharma Conspiracy Theory

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Big Pharma Conspiracy Theory The Big Pharma conspiracy theory Correspondence to: Robert Blaskiewicz Department of English Robert Blaskiewicz University of Wisconsin- Eau Claire, Eau Claire, WI University of Wisconsin-Eau Claire, Eau Claire, WI, USA USA [email protected] Abstract This essay outlines the broad themes of the conspi- pharmaceutical industry; rather it is the pharma- racy theory that pharmaceutical companies, regula- ceutical industry as they imagine it. In these tors, politicians, and others are secretly working in stories, ‘Big Pharma’ is shorthand for an abstract consort against the public interest. This so-called entity comprised of corporations, regulators, Big Pharma conspiracy theory shares a number of NGOs, politicians, and often physicians, all with a features with other conspiracy narratives, but some finger in the trillion-dollar prescription pharma- features make this particular subgenre of conspiracy ceutical pie. Eliding all of these separate entities theory especially intractable and dangerous. into a monolithic agent of evil allows the conspiracy theorist to mistakenly ignore the complex and con- Keywords: Conspiracy theory, Pharmaceutical flicting interests that they represent. This agent is, companies, Paranoia, Vaccines as are all antagonists in conspiratorial narratives, improbably powerful, competent, and craven, and it allows the conspiracy theorist to cast himself in The so-called Big Pharma conspiracy theory shares a the role of crusader and defender of a way of life, number of features with all other conspiracy the- a Manichean dichotomy that was identified in ories. First, it shares the same basic plot: a relatively Richard Hofstadter’s classic treatise on America’s small number of people are working in secret recurring conspiracism, ‘The Paranoid Style in against the public good. Second is a belief that American Politics’.1 most people are ignorant of the truth and that only Like many conspiracy theories, there may be real a small number of people with secret or suppressed tangible facts that undergird the elaborate conspi- knowledge (the conspiracy theorists) know the real racy theory. For instance, pharmaceuticals have score. Third is the conspiracy theorists’ backward side effects, many of which are unpleasant, some approach to evidence: lack of evidence for the con- of which can be fatal. This basic fact of pharma- spiracy is evidence for the conspiracy, as is any dis- cology, however, has become the basis of blanket confirming evidence. Lastly, the way supposedly claims about the universal dangerousness of confirmatory evidence is handled capitalizes on pharmaceutical products. Additionally, not all common mental shortcuts, misperceptions, and medical interventions are successful, and in our liti- non-rational cues, which make the conspiracy the- gious culture people often seem to not understand ories all the more memorable, compelling, and con- that sometimes adverse outcomes occur when tagious. This maddening mixture of mistakes makes everything is done correctly. Nowhere are these conspiracy theories very difficult to combat. ideas more prevalent than in conspiracy theories Big Pharma conspiracy theories, however, in all involving cancer treatments. Cancer treatments are their variety, constitute their own genre within the often invasive and dangerous, and while the best larger category of conspiratorial narratives. In practices, in the aggregate, improve outcomes for much the same way that the gothic novel has its patients, they can still be unpleasant, even trau- own conventions (for example, a heroine impri- matic. They may fail certain patients entirely, so soned, set in a dark old spooky house riddled that a patient may experience all of the side effects with hidden passages, and hints of the paranormal), of a treatment and none of the hoped-for benefits. the Big Pharma conspiracy theory has a number of To the conspiracist, ubiquitous advertisements by conventions that set it apart from other conspiracy pharmaceutical companies become ‘mind control’ theories. In this case, the villain is the or ‘brainwashing’, while industry lobbying Pharmaceutical Industry. It’s not the actual becomes ‘corruption’. © The European Medical Writers Association 2013 DOI: 10.1179/2047480613Z.000000000142 Medical Writing 2013 VOL. 22 NO. 4 259 Blaskiewicz – The Big Pharma conspiracy theory Conspiracy theories may be a way to reassure The big drug companies are makin’ a killing oneself that there is an order to our lives, that cala- Collectin’ the billions and gettin’ away like a mity and disaster are not meaningless or random.2 James Bond villain This in turn enables people to identify an enemy Cause they’re willin’ to do almost anything to fight. When patients (and their loved ones) are Just to make money with the flu vaccine. forced to accept a serious disease, they often experi- ence powerlessness, especially when no cure is Adams actually embraces both cui bono claims, that all available. This may itself trigger a search for a you need is vitamin D to ward off the swine flu (but culprit to blame for their suffering. Big Pharma is that drug companies can’t charge as much for it) and a convenient target and is often imagined as with- that the flu was manufactured in order to sell the holding a cure. Indeed, a major premise of the Big vaccine. He also manages to invoke a global depopu- Pharma conspiracy theory is the ‘cui bono’ fallacy: lation conspiracy alongside creating a market for vac- he who benefits from misfortune must be the cines: two agendas that are hard to reconcile, as one cause of that misfortune. Such logic has been used involves killing people and the other saving as in other, non-medical conspiracy theories: Franklin many people as possible by selling them vaccines. D Roosevelt got the war he wanted, therefore, he This is a typical feature of conspiracist thought – a was behind the Japanese attack on Pearl Harbour; 2012 study by Wood, Douglas, and Sutton found George W Bush and his handlers wanted to go to that the ‘endorsement of mutually incompatible con- war in the Middle East, so they brought down the spiracy theories are positively correlated’.4 World Trade Centre as a pretence to invade Iraq; Anti-vaccine conspiracy theories play on many of European Jews were de-ghettoized as Napoleon the same fears that run-of-the-mill Big Pharma con- swept across the continent–they must have been spiracy theories do – including fears over side behind the revolution that led to his ascent to power. effects, ‘unnatural’ substances in them and a In the case of the Big Pharma conspiracy theory, general suspicion of the profit motive in health cui bono reasoning appears in a pair of often-levelled care – but these theories are often supercharged by charges. The more common charge is that a cure is the fears of parents. Parents who believe that their being withheld to keep people on more expensive, children are ‘vaccine-damaged’ and who are strug- less effective medical regimes. In the case of gling to understand and assign blame for an intract- cancer, the cheap, easy, and ‘natural’ suppressed able, life-changing disease with no cure, have cures range from baking soda, to marijuana, to vita- created one of the most stubborn and dangerous mins, to apricot kernels (which are banned because conspiracy theories. Following the widespread the amygdalin they contain breaks down into attention received by Andrew Wakefield’s entirely hydrogen cyanide).3 The more extreme charge is fraudulent 1998 Lancet article linking the MMR that diseases are deliberately manufactured mol- vaccine to autism (withdrawn by the journal in ecule-by-molecule or weaponised in labs and 2011), childhood vaccination rates plummeted released onto the populace in order to give compa- below levels needed to support community immu- nies an excuse to sell medications. One such high- nity in many areas, and children started to contract profile accusation of this, I think, was during the diseases that many younger physicians had never 2009 H1N1 swine flu outbreak. Mike Adams, an seen. The resilience of the conspiracy theory target- inexplicably popular online health guru (he calls ing vaccine manufacturers and researchers can be himself the ‘Health Ranger’) who advocates nearly seen in the fact that it persists despite over a dozen every conspiracy theory, made this charge in 2009 studies demonstrating otherwise, including one in a bizarre little rap called ‘Don’t Inject Me (The Cochrane review that had a sample size of about Swine Flu Vaccine Song)’: 14.7 million children.5 The theory is as popular as ever and is still pushed by the likes of Jenny Don’t you know the swine flu was made by McCarthy, Generation Rescue, and innumerable man alternative medicine practitioners. Fear, it seems, is Pharmaceutical scam more contagious than reason. […] So, what can be done to combat the Big Pharma All you parents grab your kids conspiracy theory? Sadly, the theory will always be And shoot ‘em up just like guinea pigs, around because peddlers of alternative medicine find Inject your teens and your babies in the crib; Big Pharma to be a useful adversary in their quest to And when they get paralyzed, sell their questionable remedies and because of the That’s when you realize role that belief plays in people’s lives. Furthermore, There’s no way to undo what you did. once the theory has taken root in someone’smind, 260 Medical Writing 2013 VOL. 22 NO. 4 Blaskiewicz – The Big Pharma conspiracy theory it’s often impossible to dislodge it, as the conspiracy 2. Melley T. Agency panic and the culture of conspiracy. theory turns those who argue against it into ‘paid In: Knight P. editor. Conspiracy nation: the politics of paranoia in postwar America. New York: New York shills’ or ‘sheeple’.Itisbesttocatchpeoplebefore University Press; 2002. p. 57–81. they fall into conspiratorial beliefs. Secrecy and ignor- 3. Kenward M.
Load more

Recommended publications
  • Big Pharma Takes It
    A Public Eye Report – March 2021 Big Pharma takes it all How pharmaceutical corporations profiteer from their privileges – even in a global health crisis like COVID-19 1 COVID-19, SHOWCASE OF A PERVERTED BUSINESS MODEL 3 2 BIG PHARMA’S 10 STRATEGIES FOR CASHING IN 7 2.1 – Determine R & D priorities by potential profits alone 9 2.2 – Abuse patents to lock up knowledge, inflate prices and limit supply 10 2.3 – Direct the system towards the needs of high-income countries 13 2.4 – Avoid public accountability 16 2.5 – Design clinical trials for self-interest 18 2.6 – Socialise risks, privatise profits 20 2.7 – Embrace public investment, reject public returns 22 2.8 – Impose unjustifiable, unchallengeable prices 24 2.9 – Financialise innovation 29 2.10 – Lobby pervasively 31 3 SWITZERLAND IS ‘PHARMALAND’ 33 4 CONCLUSION: WHAT COVID-19 SHOWS US 37 5 TIME TO ACT: OUR DEMANDS 39 Endnotes 42 IMPRINT Big Pharma takes it all: How pharmaceutical corporations profiteer from their privileges – even in a global health crisis like COVID-19. A Public Eye Report, March 2021, 52 pages. | Authors Patrick Durisch, Gabriela Hertig | Contributors Christa Luginbühl, Oliver Classen | Edition Mary Louise Rapaud | Publishers Romeo Regenass, Ariane Bahri | Layout Karin Hutter, karinhutter.com | Icons opak.cc | Cover picture © Tang Ming Tung/Getty Images PUBLIC EYE Dienerstrasse 12, Postfach, CH-8021 Zurich | +41 (0)44 2 777 999 | [email protected] Avenue Charles-Dickens 4, CH-1006 Lausanne | +41 (0)21 620 03 03 | [email protected] Donations IBAN CH64 0900 0000 1001 0813 5, Public Eye | publiceye.ch 1 ��-19, showcase of a perverted business model Monty Rakusen/Keystone © 4 BIG PHARMA TAKES IT ALL “No one is safe until everybody is safe”, “leave no one behind” are mantras that have been oft repeated by state leaders and the World Health Organization (WHO) since the coronavirus pandemic turned our world upside down in spring, 2020.
    [Show full text]
  • The Pharma Barons: Corporate Law's Dangerous New Race to the Bottom in the Pharmaceutical Industry
    Michigan Business & Entrepreneurial Law Review Volume 8 Issue 1 2018 The Pharma Barons: Corporate Law's Dangerous New Race to the Bottom in the Pharmaceutical Industry Eugene McCarthy University of Illinois Follow this and additional works at: https://repository.law.umich.edu/mbelr Part of the Business Organizations Law Commons, Consumer Protection Law Commons, Food and Drug Law Commons, and the Rule of Law Commons Recommended Citation Eugene McCarthy, The Pharma Barons: Corporate Law's Dangerous New Race to the Bottom in the Pharmaceutical Industry, 8 MICH. BUS. & ENTREPRENEURIAL L. REV. 29 (2018). Available at: https://repository.law.umich.edu/mbelr/vol8/iss1/3 This Article is brought to you for free and open access by the Journals at University of Michigan Law School Scholarship Repository. It has been accepted for inclusion in Michigan Business & Entrepreneurial Law Review by an authorized editor of University of Michigan Law School Scholarship Repository. For more information, please contact [email protected]. THE PHARMA BARONS: CORPORATE LAW’S DANGEROUS NEW RACE TO THE BOTTOM IN THE PHARMACEUTICAL INDUSTRY Eugene McCarthy* INTRODUCTION......................................................................................... 29 I. THE RACE TO THE BOTTOM AND THE RISE OF THE ROBBER BARONS ..................................................................................... 32 A. Revising the Corporate Codes............................................ 32 B. The Emergence of Nineteenth-Century Lobbying ............. 37 C. The Robber
    [Show full text]
  • JEMH Vol4 No1 Sept
    ARTICLE SPECIAL THEME ISSUE ARTICLE Privatization of Knowledge and the Creation of Biomedical Conflicts of Interest Leemon B. McHenry Department of Philosophy, California State University, Northridge Jon N. Jureidini Discipline of Psychiatry, University of Adelaide, South Australia rather than to what is meaningful, so that fi ndings that are Abstract likely to be clinical and meaningful are rejected because they fail to reach statistical signifi cance whereas others that appear Scientifi c and ethical misconduct have increased at an clinically trivial are accepted (Ziliak and McCloskey, 2007). Th e alarming rate as a result of the privatization of knowledge. disenchantment with the psychoanalytic paradigm of psychiatry What began as an eff ort to stimulate entrepreneurship led to a massive investment in psychopharmacology and other and increase discovery in biomedical research by physical interventions. A concession now to the limited benefi t strengthening the ties between industry and academics that psychopharmacology off ers would come at great cost to the has led to an erosion of confi dence in the reporting of profession. A vested interest in protecting the new paradigm of research results. Inherent tensions between profi t-directed neurological models of psychiatric disorders reaches beyond the inquiry and knowledge-directed inquiry are instantiated quest for a secure scientifi c foundation. in psychopharmacology, especially in the co-option of academic activity to corporate objectives. The eff ects of To the vulnerability created by personal bias and questionable these tensions are visible in research agendas, publication methodology we must add the dangers of pervasive fi nancial practices, postgraduate education, academic-industry confl icts of interest, of which we investigate the root cause in this partnerships and product promotion.
    [Show full text]
  • Pharmaceutical Price Regulation
    Pharmaceutical Price Regulation Pharmaceutical Price Regulation Public Perceptions, Economic Realities, and Empirical Evidence John A. Vernon and Joseph H. Golec The AEI Press Publisher for the American Enterprise Institute WASHINGTON, D.C. Distributed to the Trade by National Book Network, 15200 NBN Way, Blue Ridge Summit, PA 17214. To order call toll free 1-800-462-6420 or 1-717-794-3800. For all other inquiries please contact the AEI Press, 1150 Seventeenth Street, N.W., Washington, D.C. 20036 or call 1-800-862-5801. Library of Congress Cataloging-in-Publication Data Vernon, John A. Pharmaceutical price regulation : public perceptions, economic realities, and empirical evidence / John A. Vernon and Joseph H. Golec. p. ; cm. Includes bibliographical references. ISBN-13: 978-0-8447-4277-9 ISBN-10: 0-8447-4277-5 1. Pharmaceutical industry—Government policy—United States. 2. Drugs—Prices—Law and legislation—United States. I. Golec, Joseph. II. Title. HD9666.6.V47 2008 338.4'361510973--dc22 2008049681 12 11 10 09 1 2 3 4 5 © 2008 by the American Enterprise Institute for Public Policy Research, Washington, D.C. All rights reserved. No part of this publication may be used or reproduced in any manner whatsoever without permission in writing from the American Enterprise Institute except in the case of brief quotations embodied in news articles, critical articles, or reviews. The views expressed in the publications of the American Enterprise Institute are those of the authors and do not necessarily reflect the views of the staff, advisory panels, officers, or trustees of AEI. Printed in the United States of America Contents LIST OF ILLUSTRATIONS vii INTRODUCTION 1 1.
    [Show full text]
  • Making Medicines Affordable: a National Imperative
    THE NATIONAL ACADEMIES PRESS This PDF is available at http://nap.edu/24946 SHARE Making Medicines Affordable: A National Imperative DETAILS 234 pages | 6 x 9 | PAPERBACK ISBN 978-0-309-46805-3 | DOI 10.17226/24946 CONTRIBUTORS GET THIS BOOK Norman R. Augustine, Guru Madhavan, and Sharyl J. Nass, Editors; Committee on Ensuring Patient Access to Affordable Drug Therapies; Board on Health Care Services; Health and Medicine Division; National Academies of Sciences, FIND RELATED TITLES Engineering, and Medicine Visit the National Academies Press at NAP.edu and login or register to get: – Access to free PDF downloads of thousands of scientific reports – 10% off the price of print titles – Email or social media notifications of new titles related to your interests – Special offers and discounts Distribution, posting, or copying of this PDF is strictly prohibited without written permission of the National Academies Press. (Request Permission) Unless otherwise indicated, all materials in this PDF are copyrighted by the National Academy of Sciences. Copyright © National Academy of Sciences. All rights reserved. Making Medicines Affordable: A National Imperative Norman R. Augustine, Guru Madhavan, and Sharyl J. Nass, Editors Committee on Ensuring Patient Access to Affordable Drug Therapies Board on Health Care Services Health and Medicine Division A Consensus Study Report of Copyright National Academy of Sciences. All rights reserved. Making Medicines Affordable: A National Imperative THE NATIONAL ACADEMIES PRESS 500 Fifth Street, NW Washington, DC 20001 This activity was supported by grants from the American College of Physicians, Breast Cancer Research Foundation, Burroughs Wellcome Fund, California Health Care Foundation, The Commonwealth Fund, Laura and John Arnold Foundation, Milbank Memorial Fund, and the Presidents’ Committee of the National Academies of Sciences, Engineering, and Medicine.
    [Show full text]
  • "Beware the Drug Companies, How They Deceive Us: 'Criticizing Big Pharma'", Global Research
    Kohls, Gary G., "Beware the Drug Companies, How they Deceive Us: 'Criticizing Big Pharma'", Global Research. Centre for Research on Globalization (CRG), Québec, Canadá, 16 de febrero de 2015. Consultado en: https://www.globalresearch.ca/beware-the-drug-companies-how-the-deceive-us-criticizing- big-pharma/5431517 Fecha de consulta: 10/10/2019 . Beware the Drug Companies, How they Deceive Us: “Criticizing Big Pharma” Pertinent Quotes from Marcia Angell, MD and Author Helen Epstein Note: Dr Marcia Angell was fired from her long-held job as executive editor of the once prestigious New England Journal of Medicine because of an editorial that she wrote criticizing the pharmaceutical industry, criticisms that she elaborated on in her book, “The Truth About the Drug Companies: How They Deceive Us and What to Do About It”. Here are some quotes from Dr Angell’s writings and/or interviews. Some of them were published at Jon Rappoport’s website: https://jonrappoport.wordpress.com/2011/05/09/faking-medical-reality/ “…Similar conflicts of interest and biases exist in virtually every field of medicine, particularly those that rely heavily on drugs or devices. It is simply no longer possible to believe much of the clinical research that is published, or to rely on the judgment of trusted physicians or authoritative medical guidelines. I take no pleasure in this conclusion, which I reached slowly and reluctantly over my two decades as an editor of The New England Journal of Medicine.” — Marcia Angell, M, author of “The Truth About the Drug Companies: How They Deceive Us and What to Do About It” “Consider the clinical trials by which drugs are tested on human subjects.
    [Show full text]
  • Immunity and Impunity: Corruption in the State-Pharma Nexus
    www.crimejusticejournal.com IJCJ&SD 2017 6(4): 86‐99 ISSN 2202–8005 Immunity and Impunity: Corruption in the State‐Pharma Nexus Paddy Rawlinson Western Sydney University, Australia Abstract Critical criminology repeatedly has drawn attention to the state‐corporate nexus as a site of corruption and other forms of criminality, a scenario exacerbated by the intensification of neoliberalism in areas such as health. The state‐pharmaceutical relationship, which increasingly influences health policy, is no exception. That is especially so when pharmaceutical products such as vaccines, a burgeoning sector of the industry, are mandated in direct violation of the principle of informed consent. Such policies have provoked suspicion and dissent as critics question the integrity of the state‐pharma alliance and its impact on vaccine safety. However, rather than encouraging open debate, draconian modes of governance have been implemented to repress and silence any form of criticism, thereby protecting the activities of the state and pharmaceutical industry from independent scrutiny. The article examines this relationship in the context of recent legislation in Australia to intensify its mandatory regime around vaccines. It argues that attempts to undermine freedom of speech, and to systematically excoriate those who criticise or dissent from mandatory vaccine programs, function as a corrupting process and, by extension, serve to provoke the notion that corruption does indeed exist within the state‐pharma alliance. Keywords State‐corporate harm; mandated vaccines; informed consent; neoliberalism. Please cite this article as: Rawlinson P (2017) Immunity and impunity: Corruption in the state‐pharma nexus. International Journal for Crime, Justice and Social Democracy 6(4): 86‐99.
    [Show full text]
  • Doctor's Dependency on Big Pharma Larissa Tiller
    The Business, Entrepreneurship & Tax Law Review Volume 2 | Issue 2 Article 12 2018 Getting Their iF x: Doctor's Dependency on Big Pharma Larissa Tiller Follow this and additional works at: https://scholarship.law.missouri.edu/betr Part of the Business Organizations Law Commons, Entrepreneurial and Small Business Operations Commons, and the Tax Law Commons Recommended Citation Larissa Tiller, Getting Their Fix: Doctor's Dependency on Big Pharma, 2 Bus. Entrepreneurship & Tax L. Rev. 492 (2018). Available at: https://scholarship.law.missouri.edu/betr/vol2/iss2/12 This Comment is brought to you for free and open access by the Law Journals at University of Missouri School of Law Scholarship Repository. It has been accepted for inclusion in The usineB ss, Entrepreneurship & Tax Law Review by an authorized editor of University of Missouri School of Law Scholarship Repository. Tiller: Getting Their Fix: Doctor's Dependency on Big Pharma Getting Their Fix: Doctor’s Dependency on Big Pharma Larissa Tiller* ABSTRACT Section 6002 of the Affordable Care Act, also known as the “Sunshine Act,” was intended to stop corrupt practices within the medical community by requiring phar- maceutical and medical device manufacturers to disclose all transfers of value of a certain amount made between them and physicians. This article suggests that the better solution to stopping corrupt practices is to ban some transfers all together. * B.A., Columbia College, Columbia, Missouri 2015; J.D. Candidate, University of Missouri School of Law, 2019. Special thanks to Benjamin Kweskin for his helpful feedback and editorial input on this article. Published by University of Missouri School of Law Scholarship Repository, 2018 1 The Business, Entrepreneurship & Tax Law Review, Vol.
    [Show full text]
  • Big Pharma Wields Its Power with the Help of Government Regulation
    Emory Corporate Governance and Accountability Review Volume 5 Issue 2 2018 Thick as Thieves? Big Pharma Wields Its Power with the Help of Government Regulation Leslie E. Sekerka Lauren Benishek Follow this and additional works at: https://scholarlycommons.law.emory.edu/ecgar Recommended Citation Leslie E. Sekerka & Lauren Benishek, Thick as Thieves? Big Pharma Wields Its Power with the Help of Government Regulation, 5 Emory Corp. Governance & Accountability Rev. 113 (2018). Available at: https://scholarlycommons.law.emory.edu/ecgar/vol5/iss2/4 This Essay is brought to you for free and open access by the Journals at Emory Law Scholarly Commons. It has been accepted for inclusion in Emory Corporate Governance and Accountability Review by an authorized editor of Emory Law Scholarly Commons. For more information, please contact [email protected]. SEKERKA_BENISHEK GALLEYFINAL 5/10/2018 12:23 PM THICK AS THIEVES? BIG PHARMA WIELDS ITS POWER WITH THE HELP OF GOVERNMENT REGULATION† Leslie E. Sekerka∗ Lauren Benishek∗∗ INTRODUCTION Americans are barraged by an endless flow of ads that claim to remedy medical maladies with prescribed drugs. The commercials depict productive and happy lives, with suggestive associations that human flourishing can be achieved via pharmaceutical intervention. The appeals are accompanied by an exhaustive inventory of potentially negative life-altering side effects. As ads end with this depiction of relational bliss through drug use, viewers hear a fast- paced listing of monotone non-segmented disclaimers,
    [Show full text]
  • Industry-Corrupted Psychiatric Trials1
    Psychiatr. Pol. 2017; 51(6): 993–1008 PL ISSN 0033-2674 (PRINT), ISSN 2391-5854 (ONLINE) www.psychiatriapolska.pl DOI: https://doi.org/10.12740/PP/80136 Industry-corrupted psychiatric trials1 Jay D. Amsterdam1, Leemon B. McHenry 2, Jon N. Jureidini3 1Depression Research Unit, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 2Department of Philosophy, California State University, Northridge, California 3Critical and Ethical Mental Health Research Group, Robinson Research Institute, University of Adelaide, Australia Summary The goal of this paper is to expose the research misconduct of pharmaceutical industry- sponsored clinical trials via three short case studies of corrupted psychiatric trials that were conducted in the United States. We discuss the common elements that enable the misrepre- sentation of clinical trial results including ghostwriting for medical journals, the role of key opinion leaders as co-conspirators with the pharmaceutical industry and the complicity of top medical journals in failing to uphold standards of science and peer review. We conclude that the corruption of industry-sponsored clinical trials is one of the major obstacles facing evidence-based medicine. Key words: antidepressants, citalopram, clinical trials, depression, ghostwriting, key opi- nion leaders, paroxetine, research misconduct, selective reporting Introduction As former editor of the New England Journal of Medicine, Marcia Angell reported in 2008: Over the past 2 decades, the pharmaceutical
    [Show full text]
  • The Firepower of the EU Pharmaceutical Lobby and Implications for Public Health 1
    Policy prescriptions the firepower of the EU pharmaceutical lobby and implications for public health 1. Table of contents Table of contents Table of contents 2 Executive summary 3 Introduction 4 1. Speaking ‘Pharmish’: the industry paradigm 5 2. Pharmaceutical industry firepower: Lobby expenditure, meetings and expertise 8 2.1. Pharmaceutical companies 10 2.2. Pharmaceutical industry trade associations 15 2.3. Lobby consultancies hired by the pharmaceutical industry 19 3. Spotlight on EFPIA: Heart of the EU pharmaceutical lobbying machine 22 3.1. The pharmaceutical industry’s European powerhouse 22 3.2. EFPIA lobby meetings with the European Commission 23 3.3. Innovative Medicines Initiative (IMI): The public-private-partnership made in heaven for EFPIA 25 4. Commission TTIPs its hat to big pharma 27 4.1. Pharma’s stake in TTIP, and why it matters 27 4.2. A front row seat for pharma in TTIP negotiations under Barroso Commission 29 4.3. The Juncker Commission: Keeping pharma close on TTIP 30 5. Conclusion 33 Appendix 34 Notes 35 Published by Corporate Europe Observatory (CEO), September 2015. Research and writing: Rachel Tansey Editing: Katharine Ainger Design: Stijn Vanhandsaeme (nestor.coop) Infographics: Ophelia Van Campenhout (nordicmaterial.com) Cover picture: iStock.com/cikailja Acknowledgements: We would like to thank Olivier Hoedeman, Martin Pigeon, Teresa Alves, Yannis Natsis, Peter Gøtzsche, Dorota Sienkiewicz, Pia Eberhardt and others for insightful input, comments and support. Contents of the report may be quoted or reproduced for non-commercial purposes, provided that the source of information is acknowledged. Erratum: The infographic on p. 11 was updated on 04/09/2015 to correct an error.
    [Show full text]
  • Big Pharma's Shameful Secret
    Bloomberg Markets Special Report TK Month 2005 COVER STORY BIG PHARMA’S SHAMEFUL SECRET Every year, drug companies spend $14 billion to test experimental substances on humans. Across the U.S., the centers that do the testing—and the regulators who watch them—allow scores of people to be injured or killed. PHOTOGRAPH BY BRIAN SMITH B l o o m b e r g M a r ke t s December 2005 37 By David Evans, Michael Smith and Liz Willen ‚Oscar Cabanerio has been waiting in an experimental America, drawn to this five-story test center in a con verted drug testing center in Miami since 7:30 a.m. The 41-year- Holiday Inn motel. Inside, the brown paint and linoleum BIG PHARMA’S old undocumented immigrant says he’s desperate for cash is gouged and scuffed. A bathroom with chipped white to send his wife and four children in Venezuela. More than tiles reeks of urine; its floor is covered with muddy foot- 70 people have crowded into reception rooms furnished prints and used paper towels. The volunteers, who are with rows of attached blue plastic seats. Cabanerio is one supposed to be healthy, wait for the chance to get paid for of many regulars who gather at SFBC International Inc.’s ingesting chemicals that may make them sick. They are SHAMEFUL test center, which, with 675 beds, is the largest for-profit testing the compounds the world’s largest pharmaceutical drug testing center in North America. companies hope to develop into best-selling medicines. Most of the people lining up at SFBC to rent their bod- Cabanerio, who has a mechanical drafting degree from SECRET ies to medical researchers are poor immigrants from Latin a technical school, says he left Venezuela because he lost SFBC’s building in Miami, a former Holiday Inn, houses the largest for-profit drug testing center in the U.S.
    [Show full text]